The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
By G. Sledge, Masakazu Toi, Patrick Neven, J. Sohn, Kenichi Inoue, X. Pivot, O. Burdaeva, M. Okera, N. Masuda, P. Kaufman and 9 more. JAMA Oncology, 2019
846 citations recorded by the source corpus.
Key Points Question Does treatment with abemaciclib plus fulvestrant prolong the overall survival (OS) of patients with hormone receptor (HR)–positive, ERBB2 (formerly HER2)-negative advanced breast cancer who progressed during prior endocrine therapy? Findings In the randomized, placebo-controlled MONARCH 2 trial of 669 patients with HR-positive, ERBB2-negative advanced breast cancer, abemaciclib plus fulvestrant significantly improved median OS to 46.7 months compared with 37.3 months for patients receiving placebo plus fulvestrant. Meaning The addition of abemaciclib to fulvestrant provided a clinically meaningful median OS benefit of 9.4 months for patients with HR-positive, ERBB2-negative advanced breast cancer that had progressed on endocrine therapy.
Subfields: Cancer Research, Oncology, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/0333661dd78f0d800c1650852bb9ac89e826eff4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020, background): “The last 2 years have seen the establishment of cyclindependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET) as the standard of care for ER-positive/HER2-negative ABC in view of the OS benefit seen in several trials,(36-42) both in the first- and second-line settings, substantial ”
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) (2020, background): “Significant improvement in OS was reported in patients with endocrineresistant disease, including patients with visceral metastases.(7) The effect now seen in the EBC adjuvant setting in monarchE indicates a similar impact on preventing early primary endocrine resistant recurrences and on reducing t”